Cantor Fitzgerald Forecasts MiMedx Group FY2026 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of MiMedx Group in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of $0.40 for the year. Cantor Fitzgerald has a "Overweight" rating and a $13.00 price objective on the stock. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, hitting analysts' consensus estimates of $0.06. The firm had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.

Separately, Wall Street Zen raised MiMedx Group from a "hold" rating to a "buy" rating in a report on Friday, June 6th.

MiMedx Group Price Performance

Shares of MDXG traded down $0.08 during midday trading on Tuesday, hitting $6.04. 939,695 shares of the company traded hands, compared to its average volume of 687,138. The firm has a 50 day moving average of $6.74 and a 200-day moving average of $7.95. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $10.14. The stock has a market cap of $892.12 million, a price-to-earnings ratio of 10.98 and a beta of 1.82. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

Hedge Funds Weigh In On MiMedx Group

Institutional investors have recently bought and sold shares of the business. Paradigm Capital Management Inc. NY raised its position in shares of MiMedx Group by 0.5% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock valued at $45,082,000 after buying an additional 22,131 shares in the last quarter. Cannell Capital LLC raised its position in MiMedx Group by 1.1% during the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock valued at $35,012,000 after purchasing an additional 40,235 shares during the period. First Light Asset Management LLC lifted its stake in shares of MiMedx Group by 3.3% in the 1st quarter. First Light Asset Management LLC now owns 3,453,074 shares of the company's stock valued at $26,243,000 after purchasing an additional 109,213 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of MiMedx Group by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock valued at $17,360,000 after purchasing an additional 280,327 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of MiMedx Group by 15.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock worth $17,338,000 after purchasing an additional 238,075 shares during the period. Institutional investors own 79.15% of the company's stock.

Insider Activity

In other MiMedx Group news, CEO Joseph H. Capper purchased 200,000 shares of MiMedx Group stock in a transaction that occurred on Friday, May 2nd. The shares were bought at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the completion of the transaction, the chief executive officer now owns 529,530 shares of the company's stock, valued at approximately $3,357,220.20. This trade represents a 60.69% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 1.70% of the company's stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.